SPL84-23, an investigational antisense oligonucleotide (ASO), restored the levels and function of CFTR — the defective protein in cystic fibrosis (CF) — in lab-grown cells from patients carrying a common and disease-causing splicing mutation, a study reported. Based on these positive preclinical findings, SpliSense plans to launch a Phase 1/2…
News
AllianceRx Walgreens Prime, a specialty and home delivery pharmacy, is partnering with TailorMed, a healthcare technology company, to help lower out-of-pocket prescription costs for specialty pharmacy patients. Medications attained through specialty pharmacies are those used to treat rare and chronic conditions in the U.S., and are often extremely costly. For…
A novel compound that may hold promise for treating the roughly 11% of cases of cystic fibrosis (CF) that are caused by nonsense mutations has been described in a new study. The study, “A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1…
Proper representation in clinical trials has long been a challenge for minorities with rare diseases like cystic fibrosis (CF), risking — and often leading to — inequities in care and fewer effective treatments for these patients. To this end, members of the CF community, including patients, researchers, physicians, and…
Kaftrio, marketed as Trikafta in the U.S., may be effective in people with cystic fibrosis (CF) who have one F508del mutation plus one other unknown mutation in the disease-causing gene, a study in cells taken from three such patients suggests. The results indicate that the combination therapy, which…
Source water levels of a metal called molybdenum is a significant environmental risk factor for nontuberculous mycobacteria (NTM) infection among people in Colorado with cystic fibrosis (CF), a database study focused on that state reported. NTM infection, caused by Mycobacterium abscessus (M. abscessus), is a difficult-to-treat bacterial infection, and…
Yap and Taz — two proteins involved in lung injury responses and regeneration — suppress the maturation of mucus-producing goblet cells and limit mucus levels in the lungs, according to a study of mice. These findings suggest that promoting Yap/Taz’s activity may be a potential therapeutic approach to limit the…
Nominations are now open for the worldwide 2022 Black Pearl Awards from Eurordis-Rare Diseases Europe. The 12 award categories recognize individual advocates, policy makers, researchers, organizations, and companies who work to make a difference for the global rare disease community. The deadline for nominations is Sept. 10…
Wrinkling on the palm of the hands after a short immersion in water may serve as a fast, easy and inexpensive test for an initial diagnosis of cystic fibrosis (CF), a study reports. Compared to healthy children in this study, those with CF developed signs of palm wrinkling — swelling,…
Inflammation in the airways of people with cystic fibrosis (CF) regulates the pH of the surface liquid and increases the response to approved CFTR modulators, a cell-based study suggested. Airway inflammation may be a key determinant in response to CF medicines, the researchers noted. “To advance personalized CFTR…
Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Recent Posts
- Plasmid gene therapy may work across CF mutations, new study suggests
- The pulmonary exacerbation and hospital stay that changed everything
- Trikafta linked to fewer hospital stays for cystic fibrosis complications
- CF transplant timing not tied to severe COVID-19 outcomes: Study
- A complicated reaction to the FDA’s expansion of CFTR modulators